Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C8H18NO2 |
| Molecular Weight | 160.234 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
CC(C[N+](C)(C)C)OC(C)=O
InChI
InChIKey=NZWOPGCLSHLLPA-UHFFFAOYSA-N
InChI=1S/C8H18NO2/c1-7(11-8(2)10)6-9(3,4)5/h7H,6H2,1-5H3/q+1
| Molecular Formula | C8H18NO2 |
| Molecular Weight | 160.234 |
| Charge | 1 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17565027Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17565027
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546
Methacholine (trade name Provocholine) is a synthetic choline ester that acts as a muscarinic receptor agonist. Methacholine is primarily used to diagnose bronchial hyperreactivity, which is the hallmark of asthma and also occurs in chronic obstructive pulmonary disease. This is accomplished through the bronchial challenge test, or methacholine challenge, in which a subject inhales aerosolized methacholine, leading to bronchoconstriction.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546 |
|||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546 |
59.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | PROVOCHOLINE Approved UseProvocholine® (methacholine chloride powder for inhalation) is indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma. Launch Date1986 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
13.83 μg/mL |
650 mg single, oral dose: 650 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRANEXAMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
80.19 μg × h/mL |
650 mg single, oral dose: 650 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRANEXAMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11.08 h |
650 mg single, oral dose: 650 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRANEXAMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
16 mg/mL 5 times / day multiple, respiratory Recommended Dose: 16 mg/mL, 5 times / day Route: respiratory Route: multiple Dose: 16 mg/mL, 5 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Bronchoconstriction... AEs leading to discontinuation/dose reduction: Bronchoconstriction (severe) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Bronchoconstriction | severe Disc. AE |
16 mg/mL 5 times / day multiple, respiratory Recommended Dose: 16 mg/mL, 5 times / day Route: respiratory Route: multiple Dose: 16 mg/mL, 5 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Developmental expression of neurokinin A and functional neurokinin-2 receptors in lung. | 2001-06 |
|
| SCF-induced airway hyperreactivity is dependent on leukotriene production. | 2001-06 |
|
| Possible involvement of Rho kinase in Ca2+ sensitization and mobilization by MCh in tracheal smooth muscle. | 2001-06 |
|
| Regulation of secretion from mucous and serous cells in the excised ferret trachea. | 2001-06 |
|
| Chronic tobacco smoke exposure increases cough to capsaicin in awake guinea pigs. | 2001-06 |
|
| Muscarinic depression of synaptic transmission in the epileptogenic GABA withdrawal syndrome focus. | 2001-05 |
|
| Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. | 2001-05 |
|
| Occupational asthma caused by exposure to cyanoacrylate. | 2001-05 |
|
| Validation of a new questionnaire on asthma, allergic rhinitis, and conjunctivitis in young adults. | 2001-05 |
|
| Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. | 2001-05 |
|
| Incidence of sensitization, symptoms, and probable occupational rhinoconjunctivitis and asthma in apprentices starting exposure to latex. | 2001-05 |
|
| Normally suppressing CD40 coregulatory signals delivered by airway macrophages to TH2 lymphocytes are defective in patients with atopic asthma. | 2001-05 |
|
| Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal. | 2001-05 |
|
| Allergen-induced changes in airway responsiveness are not related to indices of airway edema. | 2001-05 |
|
| Inhibition of m3 muscarinic acetylcholine receptors by local anaesthetics. | 2001-05 |
|
| Mutation screening of the muscarinic M(2) and M(3) receptor genes in normal and asthmatic subjects. | 2001-05 |
|
| Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans. | 2001-05 |
|
| Airways hyperresponsiveness and the effects of lung inflation. | 2001-04-18 |
|
| Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2). | 2001-04-15 |
|
| Bronchial hyperactivity in bakers and its relation to atopy and skin reactivity. | 2001-04-10 |
|
| Effect of natural allergen exposure on non-specific bronchial reactivity in asthmatic farmers. | 2001-04-10 |
|
| Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen. | 2001-04 |
|
| Reduction in atrial defibrillation threshold by a single linear ablation lesion. | 2001-04 |
|
| Changes in indices of airway hyperresponsiveness during one year of treatment with inhaled corticosteroids in patients with asthma. | 2001-04 |
|
| Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma. | 2001-04 |
|
| Glucocorticoid treatment increases inhibitory m(2) muscarinic receptor expression and function in the airways. | 2001-04 |
|
| Conditioned medium from hypoxic cytotrophoblasts alters arterial function. | 2001-04 |
|
| Mild exacerbations and eosinophilic inflammation in patients with stable, well-controlled asthma after 1 year of follow-up. | 2001-04 |
|
| Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma. | 2001-04 |
|
| Chromosome 14 linkage analysis and mutation study of 2 serpin genes in allergic asthmatic families. | 2001-04 |
|
| Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. | 2001-04 |
|
| Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. | 2001-04 |
|
| Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitized Brown Norway rats. | 2001-04 |
|
| Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. | 2001-03-27 |
|
| Effects of BCG on ovalbumin-induced bronchial hyperreactivity in a guinea pig asthma model. | 2001-03 |
|
| Comparison of the effects on drug concentrations, electrophysiologic parameters, and termination of atrial fibrillation in dogs when procainamide and ibutilide are delivered into the right atrium versus intravenously. | 2001-03 |
|
| Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum. | 2001-03 |
|
| Airway responses to a diluent used in the methacholine challenge test. | 2001-03 |
|
| High-resolution computed tomographic evaluation of airway distensibility and the effects of lung inflation on airway caliber in healthy subjects and individuals with asthma. | 2001-03 |
|
| Incidence and host determinants of probable occupational asthma in apprentices exposed to laboratory animals. | 2001-03 |
|
| Measurements of resistance by the interrupter technique and of transcutaneous partial pressure of oxygen in young children during methacholine challenge. | 2001-03 |
|
| The effect of immunotherapy on nonspecific bronchial hyperresponsiveness in bronchial asthma and allergic rhinitis. | 2001-02 |
|
| Respiratory effects of a single dive to 50 meters in sport divers with asymptomatic respiratory atopy. | 2001-02 |
|
| Bronchoconstriction induced by inhaled adenosine 5'-monophosphate in subjects with allergic rhinitis. | 2001-01 |
|
| Methacholine inhalation challenge: a shorter, cheaper and safe approach. | 2001-01 |
|
| Noninvasive method to measure airway obstruction in nonanesthetized allergen-sensitized and challenged mice. | 2001 |
|
| Bronchoconstrictor reactivity to NKA in allergic dogs: a comparison to histamine and methacholine. | 2001 |
|
| The effect of acute alteration in oxygen tension on the bronchodilator response to salbutamol in vitro and in vivo in man. | 2001 |
|
| Effect of the cyclooxygenase-2 inhibitor celecoxib on bronchial responsiveness and cough reflex sensitivity in asthmatics. | 2001 |
|
| Relationship of airway responsiveness with airway morphometry in normal and immunized rabbits. | 2001 |
Patents
Sample Use Guides
Provocholine is inhaled using a standardized procedure. The challenge is performed by giving a subject ascending serial concentrations of Provocholine. At each concentration, five breaths are administered by a nebulizer that permits intermittent delivery time of 0.6 seconds by a breath-actuated timing device (dosimeter). At each of five inhalations of a serial concentration, the subject begins at functional residual capacity (FRC) and slowly and completely inhales the dose delivered. Within 5 minutes, FEV1 values are determined. The procedure ends either when there is a 20% or greater reduction in the FEV1 compared with the baseline sodium chloride solution value (i.e., a positive response) or if 188.88 total cumulative units have been administered and the FEV1 has been reduced by 14 % or less (i.e., a negative response). If there is a reduction of 15% to 19% in the FEV, compared with baseline, either the challenge may be repeated at that concentration or a higher concentration may be given as long as the dosage administered does not result in total cumulative units exceeding 188.88.
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546
Agonist activity of methacholine was determined using assay of accumulation of [3H]inositol monophosphate. The CHO cells were labeled in 12-well plates with 1 uCi/mL myo-[3H]inositol for 24 h. Wells contained ca. 3* 10^5 cells in a volume of 1 mL. Cells were then washed once with Hank’s balanced salt media containing 20 mM HEPES buffer (pH 7.4) and were then incubated in the buffered Hank’s media containing 10 mM LiCl at room temperature for 15 min. Muscarinic agents were then added to each well. After incubation for 1 h at 37 °C, the medium was aspirated and replaced with 750 uL of cold 20 mM aqueous formic acid. After 35 min at 4 °C, the formic acid was removed and replaced with 250 uL of 60 mM NH4OH. The inositol monophosphate in the NH4OH solution was isolated by anionexchange chromatography19 and counted for tritium in Hydrofluor scintillation fluid. Cells were treated with 0.001 - 10 uM of methacholine, EC50 was determined to be 120 nM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:12:52 GMT 2025
by
admin
on
Mon Mar 31 18:12:52 GMT 2025
|
| Record UNII |
03V657ZD3V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000175369
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
||
|
NCI_THESAURUS |
C1937
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
||
|
NDF-RT |
N0000175884
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7438
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
03V657ZD3V
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
METHACHOLINE
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
155080
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID2046967
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
55-92-5
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
DB06709
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
100000085927
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
C61837
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
03V657ZD3V
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
6804
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
SUB03201MIG
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
1726
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY | |||
|
1993
Created by
admin on Mon Mar 31 18:12:52 GMT 2025 , Edited by admin on Mon Mar 31 18:12:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|